Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;29(6):611-622.
doi: 10.1080/13543784.2020.1764937. Epub 2020 May 22.

Novel emerging therapies in atherosclerosis targeting lipid metabolism

Manasvi Gupta  1 , Colin Blumenthal  2 , Subhankar Chatterjee  3 , Dhrubajyoti Bandyopadhyay  4 , Vardhmaan Jain  5 , Carl J Lavie  6 , Salim S Virani  7 , Kausik K Ray  8 , Wilbert S Aronow  9 , Raktim K Ghosh  10
Affiliations
Review

Novel emerging therapies in atherosclerosis targeting lipid metabolism

Manasvi Gupta et al. Expert Opin Investig Drugs. 2020 Jun.

Abstract

Introduction: Recent years have brought significant developments in lipid and atherosclerosis research. Although statins are a cornerstone in hyperlipidemia management, new non-statin therapies have had an impact. The reduction of low-density lipoprotein cholesterol (LDL-C) further translates into the lowering of cardiovascular mortality. Additionally, lipid research has progressed beyond LDL-C reduction and this has brought triglyceride (TG) and other apoprotein-B containing lipids into focus.

Areas covered: Inclisiran and pemafibrate, with expected approval soon, come under the spotlight. We discuss other therapeutics such as lomitapide, mipomersen, volanesorsen, and evinacumab and newly approved non-statin-based therapies such as ezetimibe, icosapent ethyl (IPE), and bempedoic acid.

Expert opinion: New options now exist for the prevention of atherosclerosis in patients that are not optimized on statin therapy. Multiple guidelines endorse ezetimibe, PCSK9 inhibitors, bempedoic, and IPE as add-on therapy. Recently approved bempedoic acid/ezetimibe combination might gain popularity among clinicians. Inclisiran and pemafibrate show promise in the reduction of LDL-C and TG, respectively, and results are pending in cardiovascular outcome trials. Combination strategies could improve outcomes, but the challenge will be balancing cost and selecting the correct patient population for each treatment modality to maximize benefit with the fewest medications.

Keywords: Atherosclerosis; CLEAR harmony; EVAPORATE; FOURIER; IMPROVE-IT; ODYSSEY; ORION-10; PCSK9 inhibitors; REDUCE-IT; bempedoic acid; evinacumab; inclisiran; lomitapide; pemafibrate; pemfibrate.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

-